IXICO provides core imaging measurement and analysis capabilities for MS clinical trials, including lesion analysis, wider brain MRI assessment, as well as spine and optic nerve structural MRI to enable sponsors to accurately assess drug safety, eligibility and efficacy.
The lesion quantification tool is embedded into the IXI™ platform to provide lesion identification, new lesions and/or assess lesion count, lesion stability and size/volume change(s).
Structural MRI for spinal cord, optic nerve analysis, Diffusion MRI, Functional MRI, Magnetic Resonance Spectroscopy (MRS) and Susceptibility.
In addition to imaging in MS, IXICO also specialises in MRI visual reads and image analysis in other demyelinating disorders, such as MOG Antibody-Associated Disease (MOGAD).
MOGAD is an autoimmune disorder causing CNS inflammation, similar to MS but triggered by MOG antibodies, leading to vision and mobility issues. Lesions are often found in the optic nerve and spinal cord, with contrast-enhanced MRI being useful in detecting active inflammation.
Fully automatic detection and quantification of new white matter lesions using deep learning
A convolutional neural network-based framework for imaging biomarkers in MS - white matter hyperintensity & brain region volumes